Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03250585 · ClinicalTrials.gov registry record
sPLA2 in EBC During Acute Chest Syndrome
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 6
- Enrollment target
NCT03250585 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 6 participants.
The verdict
NCT03250585 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Secretory phosholipases A2 (sPLA2) are significantly elevated in the plasma of sickle cell disease patients with acute chest syndrome (ACS), and similar enzymes have been measured in exhaled breath condensate (EBC), which is collected easily and non-invasively. The investigators hypothesize that sPLA2 will be measurable in EBC samples from sickle cell patients with acute chest syndrome.
Interventions
- DIAGNOSTIC_TEST Exhaled Breath Condensate (EBC)
- DIAGNOSTIC_TEST Plasma Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2018-06-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03250585
The ClinicalTrials.gov registry entry for NCT03250585 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exhaled Breath Condensate (EBC) is the first listed.
NCT03250585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03250585 about?
NCT03250585 is a clinical study titled "sPLA2 in EBC During Acute Chest Syndrome". Secretory phosholipases A2 (sPLA2) are significantly elevated in the plasma of sickle cell disease patients with acute chest syndrome (ACS), and similar enzymes have been measured in exhaled breath condensate (EBC), which is collected easily and non-invasively. The investigators hypothesize that sPL...
What is the current status of trial NCT03250585?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2018-01-19. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT03250585?
The interventions under investigation include: Exhaled Breath Condensate (EBC) (DIAGNOSTIC_TEST), Plasma Sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03250585?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.